Logo image of KLTO

KLOTHO NEUROSCIENCES INC (KLTO) Stock Overview

USA - NASDAQ:KLTO - US49876K1034 - Common Stock

0.5246 USD
-0.02 (-3.71%)
Last: 10/28/2025, 8:04:35 PM
0.5231 USD
0 (-0.29%)
After Hours: 10/28/2025, 8:04:35 PM

KLTO Key Statistics, Chart & Performance

Key Statistics
Market Cap36.90M
Revenue(TTM)N/A
Net Income(TTM)-11353900
Shares70.33M
Float54.93M
52 Week High3.91
52 Week Low0.11
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.45
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2022-04-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


KLTO short term performance overview.The bars show the price performance of KLTO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150 200

KLTO long term performance overview.The bars show the price performance of KLTO in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of KLTO is 0.5246 USD. In the past month the price increased by 8.25%. In the past year, price increased by 25.2%.

KLOTHO NEUROSCIENCES INC / KLTO Daily stock chart

KLTO Latest News, Press Relases and Analysis

KLTO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.49 401.96B
AMGN AMGEN INC 13.39 157.25B
GILD GILEAD SCIENCES INC 15.23 146.27B
VRTX VERTEX PHARMACEUTICALS INC 24.93 108.30B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.38B
REGN REGENERON PHARMACEUTICALS 14.34 69.37B
ARGX ARGENX SE - ADR 90.81 51.50B
INSM INSMED INC N/A 34.94B
ONC BEONE MEDICINES LTD-ADR 5.11 34.80B
NTRA NATERA INC N/A 26.02B
BNTX BIONTECH SE-ADR N/A 25.25B
BIIB BIOGEN INC 9.31 21.86B

About KLTO

Company Profile

KLTO logo image Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).

Company Info

KLOTHO NEUROSCIENCES INC

13576 Walnut Street, Suite A

Omaha NEBRASKA US

Employees: 3

KLTO Company Website

KLTO Investor Relations

Phone: 18339316330

KLOTHO NEUROSCIENCES INC / KLTO FAQ

What does KLOTHO NEUROSCIENCES INC do?

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. The company is headquartered in Omaha, Nebraska and currently employs 3 full-time employees. The company went IPO on 2022-04-29. The firm's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The firm's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).


Can you provide the latest stock price for KLOTHO NEUROSCIENCES INC?

The current stock price of KLTO is 0.5246 USD. The price decreased by -3.71% in the last trading session.


Does KLTO stock pay dividends?

KLTO does not pay a dividend.


How is the ChartMill rating for KLOTHO NEUROSCIENCES INC?

KLTO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the employee count for KLTO stock?

KLOTHO NEUROSCIENCES INC (KLTO) currently has 3 employees.


What is the ownership structure of KLOTHO NEUROSCIENCES INC (KLTO)?

You can find the ownership structure of KLOTHO NEUROSCIENCES INC (KLTO) on the Ownership tab.


KLTO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to KLTO. When comparing the yearly performance of all stocks, KLTO is a bad performer in the overall market: 82.18% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

KLTO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to KLTO. No worries on liquidiy or solvency for KLTO as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KLTO Financial Highlights

Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -1684.31% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -104.68%
ROE -106.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-318.75%
Sales Q2Q%N/A
EPS 1Y (TTM)-1684.31%
Revenue 1Y (TTM)N/A

KLTO Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

KLTO Ownership

Ownership
Inst Owners1.43%
Ins Owners9.22%
Short Float %1.97%
Short Ratio0.45